Tamoxifen-associated vasculitis in a breast cancer patient

World Journal of Surgical Oncology

Volumn 5, Issue , 2007, Pages

  Candelaria, Myrna ^a,b   Hurtado Monroy, Rafael ^a   Vargas Viveros, Pablo ^a   Carrillo Muñnoz, Silvia ^a   Duenas Gonzalez, Alfonso ^b,c  

^a HOSPITAL ÁNGELES DEL PEDREGAL   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; METHYLPREDNISOLONE; PREDNISONE; PROGESTERONE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANAMNESIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER PATIENT; CASE REPORT; CHOLESTASIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; KNEE ARTHRITIS; LIVER FUNCTION TEST; LYMPHADENECTOMY; MASTECTOMY; PURPURIC RASH; REVIEW; SIDE EFFECT; SKIN BIOPSY; TREATMENT INDICATION; TUMOR VOLUME; VASCULITIS; ARTICLE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; SKIN BLOOD VESSEL DISORDER;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHOLESTASIS; FEMALE; HUMANS; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SKIN DISEASES, VASCULAR; TAMOXIFEN; VASCULITIS;

EID: 33846971221     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-5-9     Document Type: Review

References (27)

1. Muti P The role of endogenous hormones in the etiology and prevention of breast cancer: The epidemiological evidence Recent Results Cancer Res 2005, 166:245-256. 15648194
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0 15894097
3. Jones KL Buzdar AU A review of adjuvant hormonal therapy in breast cancer Endocrine-Related Cancer 2004, 11:392-406.
4. Summaries for patients. Using medication to prevent breast cancer: recommendations from the United States Preventive Services Task Force Ann Intern Med 2002, 137:I62 12093267
5. Fisher B Costantino JP Redmond CK Fisher ER Wickerham DL Cronin WM Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 1994, 86:527-537. 10.1093/jnci/86.7.527 8133536
6. van Leeuwen FE Benraadt J Coebergh JW Kiemeney LA Gimbrere CH Otter R Schouten LJ Damhuis RA Bontenbal M Diepenhorst FW Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 1994, 343:448-452. 10.1016/S0140-6736(94)92692-1 7905955
7. Fisher B Dignam J Wolmark N Wickerham DL Fisher ER Mamounas E Smith R Begovic M Dimitrov NV Margolese RG Kardinal CG Kavanah MT Fehrenbacher L Oishi RH Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 1999, 353:1993-2000. 10.1016/S0140-6736(99)05036-9 10376613
8. Saphner T Tormey DC Gray R Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer J Clin Oncol 1991, 9:286-294. 1988575
9. Love RR Surawicz TS Williams EC Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy Arch Intern Med 1992, 152:317-320. 10.1001/archinte.152.2.317 1739360
10. Fisher B Costantino JP Wickerham DL Redmond CK Kavanah M Cronin WM Vogel V Robidoux A Dimitrov N Atkins J Daly M Wieand S Tan-Chiu E Ford L Wolmark N Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 1998, 90:1371-1388. 10.1093/jnci/90.18.1371 9747868
11. Dignam JJ Fisher B Occurrence of stroke with tamoxifen in NSABP B-24 Lancet 2000, 355:848-849. 10.1016/S0140-6736(05)72466-1 10711957
12. Shushan A Peretz T Uziely B Lewin A Mor-Yosef S Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer Am J Obstet Gynecol 1996, 174:141-144. 10.1016/ S0002-9378(96)70386-1 8571997
13. Nayfield SG Gorin MB Tamoxifen-associated eye disease. A review J Clin Oncol 1996, 14:1018-1026. 8622006
14. Love RR Cameron L Connell BL Leventhal H Symptoms associated with tamoxifen treatment in postmenopausal women Arch Intern Med 1991, 151:1842-1847. 10.1001/archinte.151.9.1842 1888251
15. Fisher B Constantino J Redmond C A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 1989, 320:479-484. 2644532
16. Fentiman IS Saleffi M Hamed H Studies of tamoxifen in women with mastalgia Br J Clin Pract Symp 1989, 68:34-36.
17. Rendina GM Donadio C Fabri M Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma Eur J Obstet Gynecol Reprod Biol 1984, 17:285-291. 10.1016/0028-2243(84)90071-6 6235140
18. Bonte J Ide P Billiet G Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma Gynecol Oncol 1981, 11:140-161. 10.1016/ S0090-8258(81)80003-0 6783481
19. Drago F Arditi M Rebora A Tamoxifen and purpuric vasculitis Ann Intern Med 1990, 112:965-6. 2140253
20. Batista MZ Prieto VG Chon S Hortobagyi G Esteva FJ Tamoxifen-related Vasculitis J Clin Oncol 2006, 24:3504-3505. 10.1200/JCO.2005.05.3322 16849770
21. Chitturi S Farrell GC Drug-induced cholestasis Semin Gastrointest Dis 2001, 12:113-24. 11352118
22. Richards AJ Acute inflammatory polyarthritis in association with tamoxifen Br J Rheumatol 1994, 33:998. 10.1093/rheumatology/33.10.998 7921776
23. Rutqvist L Cedermark B Glas U Randomized trial of adjuvant tamoxifen in node-negative postmenopausal breast cancer Acta oncologica 1992, 31:265-270. 1622644
24. Fisher B Dignam J Bryant J DeCillis A Wickerham DL Wolmark N Constantino J Redmond C Fisher ER Bowman DM Deschenes L Dimitrov NV Margolese RG Robidoux A Shibata H Terz J Paterson AH Feldman MI Farrar W Evans J Lickeley H Five versus more than five years of tamoxifen therapy for breast cancer patients with netative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 1996, 88:1529-1542. 10.1093/ jnci/88.21.1529 8901851
25. Baum Buzdar AU Cuzick J Forbes J Houghton J Klijn JGM Sahmoud T Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early brest cancer: First results of the ATAC randomized trial Lancet 2002, 359:2131-2139. 10.1016/S0140-6736(02)09088-8 12090977
26. Howell A Cuzick J Baum M Buzdar A Dowsett M Forbes JF Hoctin-Boes G Houghton J Locker GY Tobias JS ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 2005, 365:60-62. 10.1016/S0140-6736(05)74803-0 15639680
27. Goss PE Ingle JN Martino S Robert NJ Muss HB Piccart MJ Castiglione M Tu D Shepherd LE Pritchard KI Livingston RB Davidson NE Norton L Perez EA Abrams JS Therase P Palmer MJ Pater JL A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer New England Journal of Medicine 2003, 349:1793-1802. 10.1056/NEJMoa032312 14551341